Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group
Online Formulary

1. Gastro-intestinal system - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

 

BNF Section/s Title Issuing Body  Date of Issue/Review Update Due
1.5 Antispasmodics - Antispasmodics Position Statement - ( dicycloverine and propantheline ) Kent and Medway ICB Oct 2023 Oct 2025
1.8 Botulinum - Botulinum toxin for chronic anal fissures Kent & Medway PRGC May 2016 -
1.11 Budesonide - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis TA708 NICE Jun 2021  -
1.2.2 Constipation - Guidance on Constipation MFT/Medway & Swale CCG Jan 2020
Jan 2022
1.5 Hyoscine butylbromide - Misuse of Hyoscine butylbromide NHSPHE Jun 2015    -
1.1 Inflammatory Bowel Disease - Inflammatory Bowel Disease(IBD) (Adults) High Cost Drug Pathway    Version 1.1 Kent and Medway ICB  Dec 2023 Dec 2025
1.3 Infliximab 
ICB commissioned - approval via Blueteq - (Diarrhoea and colitis relating to ICPI therapy)
 High-Cost Drugs    
1.3 Infliximab - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy TA329 NICE  Feb 2015  - 
1.1.4 Linaclotide - Linaclotide for irritable bowel syndrome with constipation Kent & Medway PRGC Jul 2019 -
1.1.3 Mirikizumab -(Omvoh®) High-Cost Drugs    
1.1.3 Mirikizumab - Mirikizumab for treating moderately to severely active ulcerative colitis TA925 NICE Oct 2023  -
1.2.2.5 Naldemedine - Naldemedine for treating opioid-induced constipation TA651 NICE  Sep 2020 2023
1.2.2.5 Naloxegol - Naloxegol for treating opioid‑induced constipation TA345 NICE  Jul 2018   - 
1.7 Obesity - Obesity prevention CG43 NICE  Mar 2015  - 
1.4.5 Omeprazole - Omeprazole Oral suspension for Paediatrics in Primary Care– Position Statement
 Kent and Medway ICB Dec 2023 Dec 2025

1.1.3

 Ozanimod
ICB commissioned - approval via Blueteq -(Ulcerative colitis)
 High-Cost Drugs    

1.1.3

 Ozanimod - Ozanimod for treating moderately to severely active ulcerative colitis TA828
 NICE  Oct 2022  -

1.4.5

 PPI - Proton Pump Inhibitor Oral suspension for Adults Primary Care
– Position Statement		 Kent and Medway ICB Dec 2023 Dec 2025
1.1.3 Risankizumab
ICB commissioned - approval via Blueteq (Adults)
NHSE commissioned - (Adolescents 16 - 17)
 High-Cost Drugs    
1.1.3

Risankizumab -  Risankizumab for previously treated moderately to severely active Crohn's disease TA888

 NICE May 2023  - 
1.1.3

Upadacitinib

 High-Cost Drugs    

1.1.3

 Upadacitinib - Upadacitinib for previously treated moderately to severely active Crohn’s disease TA905 
 NICE Jun 2023  

1.1.3

 Upadacitinib -   Upadacitinib for treating moderately to severely active ulcerative colitis TA856 NICE Jan 2023  

1.7

(6.3.1.4)

 Wegovy - Information about Wegovy (Semaglutide) for Obesity Kent and Medway ICB Mar 2023  

1.7

(6.3.1.4)

 Wegovy - Position statement on Wegovy and GLP-1 receptor agonists (GLP-1 RAs) for weight loss
 Kent and Medway ICB Jun 2023   - 

1.7

 Wegovy - Semaglutide for managing overweight and obesity TA875    NICE Sep 2023  -

 

 

 

 

 

 

 

 

 

 

 

 

 

  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •